SPIRIT-HF missed its primary composite endpoint at 2 years, with higher observed event rates on spironolactone versus placebo ...
A large international study has found that spironolactone, a medication for high blood pressure and heart failure, does not reduce the risk of heart-related death or hospitalizations in people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results